Botulinum neurotoxins have demonstrated success in treating various pain syndromes, including central neuropathic pain, chronic musculoskeletal disorders, post-herpetic neuralgia, migraines, and trigeminal neuralgia, where the blocking of the release of CGRP and/or substance P or other neuroinflammatory agents is hypothesized to be the underlying mechanism [25,28,32,33,34]. The gene discussed is TAC1; the disease is trigeminal nerve disorder.